Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 550

1.

Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.

Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K.

Am J Psychiatry. 2005 Sep;162(9):1628-36.

PMID:
16135621
[PubMed - indexed for MEDLINE]
4.

A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.

Foy JM, Earls MF.

Pediatrics. 2005 Jan;115(1):e97-104.

PMID:
15629972
[PubMed - indexed for MEDLINE]
5.

Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.

Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal T.

J Dev Behav Pediatr. 2001 Feb;22(1):60-73.

PMID:
11265923
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.

Donnelly M, Haby MM, Carter R, Andrews G, Vos T.

Aust N Z J Psychiatry. 2004 Aug;38(8):592-601.

PMID:
15298581
[PubMed - indexed for MEDLINE]
7.

What does the MTA study tell us about effective psychosocial treatment for ADHD?

Greene RW, Ablon JS.

J Clin Child Psychol. 2001 Mar;30(1):114-21. Review.

PMID:
11294069
[PubMed - indexed for MEDLINE]
8.

Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

Foster EM, Jensen PS, Schlander M, Pelham WE Jr, Hechtman L, Arnold LE, Swanson JM, Wigal T.

Health Serv Res. 2007 Feb;42(1 Pt 1):165-82.

PMID:
17355587
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.

Faber A, van Agthoven M, Kalverdijk LJ, Tobi H, de Jong-van den Berg LT, Annemans L, Postma MJ.

CNS Drugs. 2008;22(2):157-70.

PMID:
18193926
[PubMed - indexed for MEDLINE]
10.

Effectiveness of an adaptive multimodal treatment in children with Attention-Deficit Hyperactivity Disorder -- global outcome.

Döpfner M, Breuer D, Schürmann S, Metternich TW, Rademacher C, Lehmkuhl G.

Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I117-29.

PMID:
15322962
[PubMed - indexed for MEDLINE]
11.

Special considerations in diagnosing and treating attention-deficit/hyperactivity disorder.

Wigal SB, Wigal TL.

CNS Spectr. 2007 Jun;12(6 Suppl 9):1-14; quiz 15-6. Review.

PMID:
17545959
[PubMed - indexed for MEDLINE]
12.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

PMID:
16796929
[PubMed - indexed for MEDLINE]
Free Article
13.

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.

Value Health. 2008 May-Jun;11(3):376-88. doi: 10.1111/j.1524-4733.2007.00256.x.

PMID:
18489664
[PubMed - indexed for MEDLINE]
14.

Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder.

Wells KC, Chi TC, Hinshaw SP, Epstein JN, Pfiffner L, Nebel-Schwalm M, Owens EB, Arnold LE, Abikoff HB, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March J, Newcorn JH, Pelham WE, Severe JB, Swanson J, Vitiello B, Wigal T.

J Consult Clin Psychol. 2006 Aug;74(4):649-57.

PMID:
16881772
[PubMed - indexed for MEDLINE]
15.

Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.

Guevara J, Lozano P, Wickizer T, Mell L, Gephart H.

Pediatrics. 2001 Jul;108(1):71-8.

PMID:
11433056
[PubMed - indexed for MEDLINE]
16.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
[PubMed - indexed for MEDLINE]
17.

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M.

Clin Ther. 2001 Nov;23(11):1904-21.

PMID:
11768842
[PubMed - indexed for MEDLINE]
18.

In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder.

Cunningham CE.

Can J Psychiatry. 1999 Dec;44(10):999-1006. Review.

PMID:
10637679
[PubMed - indexed for MEDLINE]
19.

The management of patients with attention-deficit hyperactivity disorder by family practitioners.

Eppright TD, Bradley S, Vogel SJ, Williamson HA.

Mo Med. 1998 Mar;95(3):118-22.

PMID:
9529896
[PubMed - indexed for MEDLINE]
20.

Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99.

Robison LM, Sclar DA, Skaer TL, Galin RS.

Int Clin Psychopharmacol. 2004 Jan;19(1):17-22.

PMID:
15101565
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk